CKD-845 Pharmacokinetics and Safety Study in Males with Hypogonadism

Phase 1, randomised, single-blind trial of testosterone in male hypogonadism (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Baseline corrected Area Under the Concentration-time Curve from time zero to the last measurable concentration up to 70 days and Baseline corrected Maximum Plasma Concentration up to 70 days. Started Nov 2020; status: completed.